This rearrangement is similar to that of ALK and is seen also in glioblastoma, cholangiocarcinoma, ovarian carcinoma, angiosarcomas, etc. Aberrant ROS1 can activate multiple oncogenic pathways downstream, thus leading to tumor proliferation and survival. This evidence concerns the gene ALK and neoplasm.